Infectious colitis medical therapy: Difference between revisions

Jump to navigation Jump to search
Line 20: Line 20:
===Pathogen Specific===
===Pathogen Specific===
*The mainstay of therapy is given antimicrobials against the specific identified pathogen.<ref name="pmid22080825">{{cite journal| author=DuPont HL| title=Approach to the patient with infectious colitis. | journal=Curr Opin Gastroenterol | year= 2012 | volume= 28 | issue= 1 | pages= 39-46 | pmid=22080825 | doi=10.1097/MOG.0b013e32834d3208 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22080825  }} </ref><ref name="pmid11170940">{{cite journal| author=Guerrant RL, Van Gilder T, Steiner TS, Thielman NM, Slutsker L, Tauxe RV et al.| title=Practice guidelines for the management of infectious diarrhea. | journal=Clin Infect Dis | year= 2001 | volume= 32 | issue= 3 | pages= 331-51 | pmid=11170940 | doi=10.1086/318514 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11170940  }} </ref>
*The mainstay of therapy is given antimicrobials against the specific identified pathogen.<ref name="pmid22080825">{{cite journal| author=DuPont HL| title=Approach to the patient with infectious colitis. | journal=Curr Opin Gastroenterol | year= 2012 | volume= 28 | issue= 1 | pages= 39-46 | pmid=22080825 | doi=10.1097/MOG.0b013e32834d3208 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22080825  }} </ref><ref name="pmid11170940">{{cite journal| author=Guerrant RL, Van Gilder T, Steiner TS, Thielman NM, Slutsker L, Tauxe RV et al.| title=Practice guidelines for the management of infectious diarrhea. | journal=Clin Infect Dis | year= 2001 | volume= 32 | issue= 3 | pages= 331-51 | pmid=11170940 | doi=10.1086/318514 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=11170940  }} </ref>
*The specific antimicrobial treatment of infectious colitis depends on the pathogen causing infectious colitis as follows:
*[[Shigellosis#Medical therapy|''Shigella spp.'']]
*[[Campylobacteriosis#Medical therapy|''Campylobacter jejuni'']]
*[[Clostridium difficile infection#Medical therapy|''Clostridium difficile'']]
*[[Escherichia coli enteritis#Medical therapy|''Escherichia coli'']]
*[[Salmonellosis#Medical therapy|Nontyphoidal ''Salmonella'']]
*[[Amoebiasis#Medical therapy|''Entameoba histolytica'']]
*[[Lymphogranuloma venereum#Medical therapy|''Chlamydia trachomatis'']]
*[[Cytomegalovirus infection#Medical therapy|''Cytomegalovirus'']]
*[[Yersinia enterocolitica infection#Medical therapy|''Yersinia enterocolitica'']]


==References==
==References==
{{Reflist|2}}
{{Reflist|2}}
{{WS}}{{WH}}
{{WS}}{{WH}}

Revision as of 20:44, 30 October 2016

Colitis Main Page

Infectious colitis Microchapters

Home

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Infectious colitis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Endoscopy

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Infectious colitis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Infectious colitis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Infectious colitis medical therapy

CDC on Infectious colitis medical therapy

Infectious colitis medical therapy in the news

Blogs on Infectious colitis medical therapy

Directions to Hospitals Treating Uveitis

Risk calculators and risk factors for Infectious colitis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Qasim Salau, M.B.B.S., FMCPaed [2]

Overview

The mainstay of treatment of infectious colitis is the administration of antimicrobials against the causative pathogen. In addition to antimicrobial therapy, general supportive measures is usually given to replace fluid and electrolytes and occasionally blood.

Medical Therapy

The mainstay of treatment of infectious colitis is the administration of antimicrobials against the causative pathogen. In addition to antimicrobial therapy, general supportive measures is usually given to replace fluid and electrolytes and occasionally blood.

Symptomatic Treatment

  • Symptomatic treatment for infectious colitis involves the patient consuming adequate amounts of water to correct dehydration, preferably mixed with electrolytes to provide essential salts and some amount of nutrients. Antimotility therapy is generally not indicated and may even be deleterious in the treatment of infectious colitis.[1][2]
  • The following supportive measures/ advice can be given:
    • Fluid resuscitation (oral, if not IV)
    • Patients should be advised to do the following until symptoms subside:
    • Hydrate with liquids that are caffeine free
    • Avoid lactose
    • Eating fresh fruit


Pathogen Specific

  • The mainstay of therapy is given antimicrobials against the specific identified pathogen.[1][2]
  • The specific antimicrobial treatment of infectious colitis depends on the pathogen causing infectious colitis as follows:

References

  1. 1.0 1.1 DuPont HL (2012). "Approach to the patient with infectious colitis". Curr Opin Gastroenterol. 28 (1): 39–46. doi:10.1097/MOG.0b013e32834d3208. PMID 22080825.
  2. 2.0 2.1 Guerrant RL, Van Gilder T, Steiner TS, Thielman NM, Slutsker L, Tauxe RV; et al. (2001). "Practice guidelines for the management of infectious diarrhea". Clin Infect Dis. 32 (3): 331–51. doi:10.1086/318514. PMID 11170940.

Template:WSTemplate:WH